Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis

Mov Disord. 2010 Jul 30;25(10):1456-63. doi: 10.1002/mds.23111.

Abstract

The long-term benefits of subthalamic nucleus deep brain stimulation (STN DBS) applied earlier in the disease course, before significant disability accumulates, remain to be determined. We developed a Markov state transition decision analytic model to compare effectiveness in quality-adjusted life years (QALYs) of STN DBS applied to patients with PD at an "early" ("off time" 10-20%) versus "delayed" stage ("off time" >40%). A lifelong time horizon and societal perspective were assumed. Probabilities and rates were obtained from literature review; utilities were derived using the time trade-off technique and a computer-assisted utility assessment software tool applied to a cohort of 22 STN-DBS and 21 non-STN-DBS PD patients. Uncertainty was assessed through one- and two-way sensitivity analyses and probabilistic sensitivity analysis using second-order Monte Carlo simulations. Early STN DBS was preferred with a quality-adjusted life expectancy of 22.3 QALYs, a gain of 2.5 QALYs over those with delayed surgery (19.8 QALYs). Early STN DBS was preferred in 69% of 5,000 Monte Carlo simulations. Early surgery was robustly favored through most sensitivity analyses. Delayed STN DBS afforded greater QALYs when using utility estimates exclusively from non-STN-DBS patients and, for the entire group, if the rate of motor progression were to exceed 25% per year. Although decision modeling requires assumptions and simplifications, our exploratory analysis suggests that STN DBS performed in early PD may convey greater quality-adjusted life expectancy when compared to a delayed procedure. These findings support further evaluation of early STN DBS in a controlled clinical trial.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Cognition Disorders / etiology
  • Cognition Disorders / psychology
  • Decision Support Techniques*
  • Deep Brain Stimulation / methods*
  • Female
  • Humans
  • Male
  • Markov Chains
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / psychology
  • Parkinson Disease / therapy*
  • Quality of Life
  • Subthalamic Nucleus / physiology*
  • Time Factors
  • Treatment Outcome

Substances

  • Antiparkinson Agents